Charles River Laboratories International, INC

Charles River Laboratories International, Inc. shareholders approved the 2026 Long-Term Incentive Plan at the annual meeting, alongside the election of directors and ratification of auditors.

Charles River Laboratories reported Q1 2026 results with revenue increasing 1.2% year-over-year to $995.8 million, while GAAP loss per share was $(0.30) and non-GAAP EPS was $2.06, down from the prior year.

Charles River Laboratories announced definitive agreements to divest its CDMO, Cell Solutions, and certain European Discovery Services businesses, updating its 2026 financial guidance.

Charles River Laboratories International, Inc. provided an optimistic 2026 outlook, citing improving demand trends in its Discovery and Safety Assessment business and announcing two strategic acquisitions.

Charles River Laboratories International, Inc. announced a leadership transition plan, with Birgit Girshick appointed as the new CEO, succeeding James C. Foster, effective May 5, 2026.

Charles River Laboratories International, Inc. reports continued improvement in Discovery and Safety Assessment net book-to-bill trends since Q3 2025, despite potential holiday seasonality.

Charles River Laboratories International, Inc. reported a slight revenue decrease for Q3 2025 and the nine months ended September 27, 2025, alongside a significant drop in net income for the nine-month period, as it navigates a cautious client spending environment and implements a comprehensive strategic review.

Charles River Laboratories International, Inc. reported a significant decline in Q2 2025 net income and operating profit, primarily due to accelerated amortization and substantial restructuring costs, despite a slight revenue increase.

Charles River Laboratories' Q1 2025 results reveal a decrease in revenue and operating income, primarily due to cautious client spending and restructuring activities.

Charles River Laboratories experienced a slight revenue decrease in Q3 2024, alongside restructuring efforts impacting profitability.

Charles River Laboratories' second-quarter results show a revenue decrease and a drop in operating income, influenced by a cautious spending environment and restructuring activities.

Charles River Laboratories' first quarter results show a slight revenue decrease and a significant drop in operating income, influenced by restructuring costs and ongoing legal issues.

Charles River Laboratories reports a decrease in revenue and operating income for fiscal year 2024, impacted by industry-wide challenges and restructuring activities.

Charles River Laboratories' 2023 annual report reveals a year of revenue growth tempered by economic caution and strategic adjustments.

Director James C. Foster of Charles River Laboratories International, Inc. reported a sale of 75,000 common shares, executed under a pre-established Rule 10b5-1 trading plan.

Charles River Laboratories director James C. Foster reported a series of transfers of common stock to various trusts on June 5, 2026, involving over 183,000 shares.

Birgit Girshick, CEO of Charles River Laboratories, transferred 3,386 shares to a revocable trust she controls.

Shannon M. Parisotto, EVP of Discovery & Safety Assessment at Charles River Laboratories, reported a transfer of 1,529 common shares to a revocable trust.

Director Steven Barg acquired 422 shares of Charles River Laboratories International, Inc. as part of a stock-based compensation plan for director service fees.

Glenn Coleman, EVP & Chief Financial Officer of Charles River Laboratories International, Inc., acquired 6,640 shares of common stock.

Charles River Laboratories International, Inc. announces a leadership transition with CEO James C. Foster's retirement, the appointment of Birgit Girshick as his successor, and proposals for a new long-term incentive plan and director elections at its 2026 Annual Meeting.

Charles River Laboratories International, Inc. is set to hold its 2025 Annual Meeting of Shareholders on May 20, 2025, featuring proposals including director elections, executive compensation, auditor ratification, and a shareholder proposal concerning nonhuman primate imports.

Charles River Laboratories files a supplement to its proxy statement, reiterating its opposition to a shareholder proposal requesting a report on non-human primates (NHPs) imported by the company, arguing that existing disclosures already meet and exceed the proposal's requests.

Charles River Laboratories announces its 2024 Annual Meeting of Shareholders to be held on May 8, 2024, in Boston.

Invesco Ltd. has filed a Schedule 13G, reporting beneficial ownership of 4.9% of Charles River Laboratories International Inc. common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 7.0% of Charles River Laboratories International Inc. common stock as of March 31, 2026.

Vanguard Capital Management has reported a beneficial ownership of 7.38% in Charles River Laboratories International Inc., holding 3,634,376 shares.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Charles River Laboratories International Inc. following an internal realignment.

Invesco Ltd. has reported a 5.5% beneficial ownership stake in Charles River Laboratories International Inc. common stock.

Wellington Management Group and its affiliates reported a 3.55% beneficial ownership stake in Charles River Laboratories International, Inc. common stock as of December 31, 2025.